Every 8-K that IN8bio, Inc. (INAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on γδ T cell therapies, reported results for the second quarter ended June 30, 2026. The company recorded a net loss of $4.8 million, or $0.25 per share, compared with a net loss of $5.1 million, or $1.24 per share, a year earlier. Research and development expenses were $2.5 million and general and administrative expenses were $2.4 million. Cash was $18.0 million as of June 30, 2026, compared with $13.2 million in the prior-year period.
IN8bio highlighted progress across its pipeline, including advancing INB-619, a CD19-targeting γδ T cell engager, into IND-enabling studies, with initial in vivo preclinical data expected in the second half of 2026. Updated data from the DeltEx DRI glioblastoma program showed median progression-free survival of 13.0 months versus 6.6 months for standard-of-care and median overall survival exceeding 19.5 months versus 13.2 months. Additional translational analyses showed an 18-fold increase in intratumoral CD8+ T cells and a 90% reduction in immunosuppressive granulocytes after repeated DeltEx DRI dosing.
IN8bio, Inc. has put a new at-the-market stock offering program in place and ended its prior one. On June 1, 2026, the company entered into a Capital on Sales Agreement with JonesTrading Institutional Services, allowing IN8bio to issue and sell common stock from time to time at its sole discretion under its existing Form S-3 shelf registration. JonesTrading will use commercially reasonable efforts to sell any shares and will earn a 3.0% commission on gross sales proceeds, while IN8bio has no obligation to sell any stock and either party can terminate the agreement on written notice.
The company also terminated its earlier Controlled Equity Sales Agreement with Cantor Fitzgerald & Co., effective May 29, 2026. Both parties waived the original advance notice requirements, and IN8bio is not subject to any termination penalties. After this termination, no additional shares may be issued or sold under the Cantor agreement or its related prospectus.
IN8bio, Inc. reported first quarter 2026 results and highlighted progress in its γδ T cell pipeline. Net loss was $5.1 million, or $0.26 per share, compared with a $5.6 million loss a year earlier, as R&D expenses fell modestly to $2.6 million.
Updated clinical data in newly diagnosed glioblastoma showed median progression-free survival of 13.0 months for repeat-dose patients versus 6.6 months for standard-of-care, and median overall survival of 17.2+ months versus 13.2 months, with no dose-limiting toxicities or cytokine release syndrome reported.
Stockholders approved the Amended and Restated 2026 Equity Incentive Plan, adding 2,920,000 shares available for awards, extending the annual share increase through 2037, and setting a 20,000,000-share cap for incentive stock options. Director nominees and the independent auditor were also ratified by wide margins.
IN8bio, Inc. reported fourth quarter and full-year 2025 results, highlighting clinical progress in glioblastoma, a strengthened balance sheet and lower losses. Repeat dosing of its DeltEx DRI γδ T cells in newly diagnosed GBM achieved median progression-free survival of 13.0 months versus 6.6 months for a standard-of-care cohort, with no dose-limiting toxicities or serious unexpected safety issues reported.
The company closed an initial $20.1 million tranche of a private placement of up to $40.2 million, with net proceeds of $18.5 million expected to extend its cash runway into the first half of 2027. Cash was $27.1 million as of December 31, 2025, up from $11.1 million a year earlier. Full-year net loss narrowed to $19.4 million, or $4.44 per share, from $30.4 million, or $17.05 per share, driven by lower R&D and G&A expenses.
IN8bio is advancing its INB-200/400 GBM programs, INB-100 for high-risk leukemias, and the INB-600 γδ T cell engager platform, including INB-619 heading into IND-enabling studies. The company outlined multiple 2026 milestones, including FDA guidance on regulatory pathways, additional GBM data and initial INB-619 animal data.
IN8bio, Inc. reported that director Alan S. Roemer has notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company states that his resignation is not due to any disagreement with IN8bio, its management, the Board, or any Board committee on matters related to operations, policies, or practices.
The Board has appointed independent director Jeremy Graff as Interim Chair of the Board, effective the same date. This change reflects a governance and leadership transition at the Board level without any financial results or major transactions described in this report.
IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026. She will hold both roles of President and Chief Operating Officer, providing continuity in executive leadership. The company notes that there are no family relationships or related-party transactions involving Dr. Rochlin that require disclosure under the SEC’s executive and related-party rules.
IN8bio, Inc. reported that it presented consolidated clinical data from two glioblastoma studies at the 2025 Society for Neuro-Oncology Annual Meeting. The update covered an investigator-sponsored Phase 1 single-center trial of INB-200 and a Company-sponsored Phase 2 multi-center trial of INB-400 in patients with newly diagnosed glioblastoma.
The company delivered these results in both poster and oral presentations on November 21 and 22, 2025, highlighting progress in its gamma-delta T cell therapy programs for this aggressive brain cancer.
IN8bio (INAB) reported that it furnished a press release announcing financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The disclosure is provided under Item 2.02 of an 8‑K and, along with Exhibit 99.1, is designated as “furnished,” not “filed,” under the Exchange Act. IN8bio’s common stock trades on Nasdaq under the symbol INAB.
IN8bio, Inc. (INAB) filed an 8-K announcing new preclinical data from its gamma delta T cell engager program, INB-619. The company said the data will be presented at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago.
A company press release with additional details is attached as Exhibit 99.1 and incorporated by reference. This filing does not include financial results or transaction terms; it primarily serves to notify investors of the scientific presentation and provide the related press release.